Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENOCHIAN BIOSCIENCES, INC.

(ENOB)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ENOCHIAN BIOSCIENCES INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

09/13/2021 | 08:17am EDT

Item 7.01 Regulation FD Disclosure.

Enochian Biosciences Inc., a Delaware corporation (the "Company"), today has made available an Investor Presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, during which our Chief Executive Officer, Dr. Mark Dybul, participated in a webcast. The Investor Presentation is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

The information included in this Item 7.01 and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

The Company undertakes no duty or obligation to update or revise information included in this Report or the Exhibit.

Item 9.01 Financial Statements and Exhibits.





  (d)  Exhibits




EXHIBIT NO.     DESCRIPTION                 LOCATION
  99.1            Investor Presentation       Furnished herewith

© Edgar Online, source Glimpses

All news about ENOCHIAN BIOSCIENCES, INC.
10/19Enochian Biosciences, Inc. Announces Potential Cure for IV Successfully Completes Pre-I..
CI
10/18ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 month
PU
10/18ENOCHIAN BIOSCIENCES : Completes FDA Pre-IND for HIV Antiviral Therapy; Shares Down in Pre..
MT
10/18Enochian BioSciences Completes Pre-IND After FDA Comments
DJ
10/18ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 month
AQ
10/18ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 Month
CI
10/15ENOCHIAN BIOSCIENCES : Scientific Advisory Board Member Resigns Due to Conflict with Respo..
PU
10/15ENOCHIAN BIOSCIENCES : Scientific Advisory Board Member Resigns Due toáConflict with Respo..
AQ
10/15Enochian Biosciences, Inc. Announces Resignation of Peter Piot as Chairperson of the Re..
CI
10/12ENOCHIAN BIOSCIENCES : Fireside Chat with Enochian BioSciences' CEO, Dr. Mark Dybul at H.C..
PU
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -26,7 M - -
Net cash 2021 13,3 M - -
P/E ratio 2021 -8,77x
Yield 2021 -
Capitalization 462 M 462 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 11
Free-Float 38,5%
Chart ENOCHIAN BIOSCIENCES, INC.
Duration : Period :
Enochian Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENOCHIAN BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Mark Richard Dybul Executive Vice Chairman & Chief Executive Officer
Luisa Puche Chief Financial Officer
Rene Sindlev Chairman
Joseph R. Cohen Director-Research & Discovery
Carl Sandler Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ENOCHIAN BIOSCIENCES, INC.199.66%462
GILEAD SCIENCES, INC.16.15%84 845
BIONTECH SE261.78%71 229
WUXI APPTEC CO., LTD.24.08%64 399
REGENERON PHARMACEUTICALS19.27%59 906
VERTEX PHARMACEUTICALS-21.73%47 992